Literature DB >> 19519309

Prediction of conversion from mild cognitive impairment to Alzheimer's disease by CSF cytochrome c levels and N200 latency.

V T Papaliagkas1, G Anogianakis, M N Tsolaki, G Koliakos, V K Kimiskidis.   

Abstract

The aim of the present study was to investigate the role of CSF cytochrome c levels and auditory event-related potentials (AERPs) on the progress of mild cognitive impairment (MCI) to Alzheimer's disease (AD). Fifty one patients diagnosed with MCI and fourteen healthy individuals underwent lumbar puncture at baseline and their CSF cytochrome c levels were determined. A follow-up examination of cytochrome c levels took place in 20 patients after 11 months and in this period five of the patients progressed to AD. ERP examinations were also performed in all patients both at baseline and follow-up. MCI patients had significantly higher cytochrome c levels compared to healthy controls (Mann-Whitney test, Z=-2.110, p=0.018). Compared to MCI patients who remained stable, the AD-converters, had a higher increase over time in cytochrome c levels (Mann-Whitney test, p=0.002; effect size r=0.63) and significantly prolonged N200 latency (Mann-Whitney test, p<0.001; effect size r=0.50). Amongst investigated ERP variables, only N200 amplitude was significantly correlated with CSF cytochrome c levels (rs=0.310, p=0.03). Both parameters were proved capable of discriminating AD converters from those MCI patients who remained stable, with sensitivity and specificity >75%. Our results suggest that conversion from MCI to AD is associated with a marked elevated N200 latency at baseline and a high increase in cytochrome c levels during a relatively short period of time, and that both parameters could be possibly considered as candidate markers for the discrimination between MCI patients who convert to AD and those who remain stable.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19519309     DOI: 10.2174/156720509788486626

Source DB:  PubMed          Journal:  Curr Alzheimer Res        ISSN: 1567-2050            Impact factor:   3.498


  6 in total

1.  Predicting conversion from mild cognitive impairment to Alzheimer's disease using neuropsychological tests and multivariate methods.

Authors:  Robert M Chapman; Mark Mapstone; John W McCrary; Margaret N Gardner; Anton Porsteinsson; Tiffany C Sandoval; Maria D Guillily; Elizabeth Degrush; Lindsey A Reilly
Journal:  J Clin Exp Neuropsychol       Date:  2010-08-13       Impact factor: 2.475

2.  Application of Concordance Probability Estimate to Predict Conversion from Mild Cognitive Impairment to Alzheimer's Disease.

Authors:  Xiaoxia Han; Yilong Zhang; Yongzhao Shao
Journal:  Biostat Epidemiol       Date:  2017-07-31

3.  Increased cytochrome c in rat cerebrospinal fluid after cardiac arrest and its effects on hypoxic neuronal survival.

Authors:  Hao Liu; Syana M Sarnaik; Mioara D Manole; Yaming Chen; Sunita N Shinde; Wenjin Li; Marie Rose; Henry Alexander; Jie Chen; Robert S B Clark; Steven H Graham; Robert W Hickey
Journal:  Resuscitation       Date:  2012-05-01       Impact factor: 5.262

Review 4.  Bioenergetic dysfunction and inflammation in Alzheimer's disease: a possible connection.

Authors:  Heather M Wilkins; Steven M Carl; Alison C S Greenlief; Barry W Festoff; Russell H Swerdlow
Journal:  Front Aging Neurosci       Date:  2014-11-10       Impact factor: 5.750

5.  Emerging perspectives on mitochondrial dysfunction and inflammation in Alzheimer's disease.

Authors:  Seung-Min Yoo; Jisu Park; Seo-Hyun Kim; Yong-Keun Jung
Journal:  BMB Rep       Date:  2020-01       Impact factor: 4.778

6.  Mismatch negativity as EEG biomarker supporting CNS drug development: a transnosographic and translational study.

Authors:  Simon Loiodice; Wilhelmus H Drinkenburg; Abdallah Ahnaou; Andrew McCarthy; Geoffrey Viardot; Emilie Cayre; Bertrand Rion; Valérie Bertaina-Anglade; Marsel Mano; Philippe L'Hostis; Christophe Drieu La Rochelle; Martien J Kas; Philippe Danjou
Journal:  Transl Psychiatry       Date:  2021-04-29       Impact factor: 6.222

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.